placebo Type of group
Sponsors
SCHERING PLOUGH RESEARCH INSTITUTE,, PHARMACIA & UPJOHN INTERAMERICAN CORPORATION,, MERCK SHARP & DOHME PERU S.R.L.,, GLAXOSMITHKLINE PERU S.A.,, ASTRAZENECA - PERU,
Early Phase 1
INTERNATIONAL MULTICENTRIC STUDY OF ANASTROZOL VS. PLACEBO IN POST-MENOPAUSIC WOMEN WITH HIGH RISK OF BREAST CANCER IBIS II (PREVENTION).
Active, not recruitingPER-039-03
Target: 20Updated: 2023-09-04
MULTICENTRIC, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK-0767 ADDED TO INSULIN THERAPY IN PATIENTS WITH DIABETES MELLITUS TYPE 2 CONTROLLED INADECUATELY.
Active, not recruitingPER-045-03
Target: 25Updated: 2023-09-04
STUDY RANDOMIZED, OF 3 PERIODS OF MULTIPLE DOSE, MULTICENTRIC TO EVALUATE THE SAFETY, TOLERABILITY AND THE PROFILE OF PLASMA CONCENTRATION OF MONTELUKAST ADMINSTRATED ONCE A DAY IN ORAL GRANULES TO CHILDREN FROM 3 TO 6 MONTHS OF AGE.
Active, not recruitingPER-042-03
Target: 3Updated: 2023-09-04
Unknown Phase
A DOUBLE BLIND COMPARISON CONTROLLED WITH PLACEBO, RANDOMIZED OF THE EFFICACY AND SAFETY OF CELECOXIB 200 MG AND CELECOXIB 400MG ONCE A DAY IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF PSORIASTIC ARTHRITIS
Active, not recruitingPER-018-02
Target: 15Updated: 2023-09-04
MULTICENTRIC STUDY DOUBLE BLIND, RANDOMIZED, PARALLEL, CONTROLLED WITH PLACEBO AND ACTIVE CONTROLLER TO EVALUATE THE EFFECTIVENESS AND SAFETY OF L-410198 IN THE ALTERATION OF LIPIDS IN PATIENTS THAT SUFFER FROM METABOLIC SYNDROME AND DYSLIPIDEMIAS
Active, not recruitingPER-020-02
Target: 30Updated: 2023-09-04
A Double-Blind, Multicenter, Placebo and Active-Controlled, Acute Extension Study of 2 Doses of MK-0869 in the Treatment of Patients With Major Depressive Disorder
Active, not recruitingPER-021-02
Target: 32Updated: 2023-09-04
A MULTI-CENTER STUDY OF 52 WEEKS, RANDOMIZED, DOUBLE-BLIND, DOUBLED MASKED, CONTROLLED WITH PLACEBO AND PARALLEL GROUPS, TO COMPARE THE EFFECTIVENESS AND TOLERABILITY OF THE COMBINATION WITH SALMETEROL / PROPIONATO DE FLUTICASONA (SERETIDE / VIANI / ADV)
Active, not recruitingPER-026-02
Target: 13Updated: 2023-09-04
MULTINATIONAL, MULTICENTRIC, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY, IN PARALLEL GROUPS, TO EVALUATE THE EFFICACY OF ZOLEDRONIC ACID ADMINSTRATED BY INTRAVENOUS VIA IN THE PREVENTION OF OSTEOPOROTIC FRACTURES AFTER A HIP FRACTURE.
Active, not recruitingPER-061-02
Updated: 2023-09-04
STUDY PHASE III, RANDOMIZED, DOUBLE-BLIND AND CONTROLLED BY PLACEBO, TO EVALUATE THE CLINICAL CONSISTENCY OF THREE LOTS OF VACCINE PRODUCTION HRV OF GSK BIOLOGICALS IN IMMUNOGENICITY AND SECURITY TERMS, WHEN ADMISSION TO HEALTHY INFANTS AT 2 AND 4 MONTHS OF AGE .
Active, not recruitingPER-046-03
Target: 450Updated: 2023-09-04
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTRIC STUDY TO EVALUATE THE EFFECTS OF ROFECOXIB IN REDUCING THE RISK OF PROSTATE CANCER (VIP STUDY).
Active, not recruitingPER-047-03
Target: 41Updated: 2023-09-04
Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer
Active, not recruitingPER-003-04
Target: 5Updated: 2023-09-04
AN EXTENSION OF THE MONDRIAN STUDY: OPEN SAFETY EXTENSION OF STUDY SLV308 S308.3.002 IN PATIENTS WITH PARKINSON DISEASE EXPERIENCING MOTOR FLUCTUATIONS
Active, not recruitingPER-070-07
Target: 30Updated: 2023-09-04
A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTI CENTER STUDY OF OT 101 IN HOSPITALIZED COVID 19 SUBJECTS
Active, not recruitingPER-067-20
Start: 2020-09-18Target: 48Updated: 2023-09-04